Novo's real-world study found that patients switching from obesity injections to its new Wegovy pill continued losing weight, with participants losing an average of 4% of body weight over three months. The analysis suggests the pill may offer greater convenience than weekly injections while maintaining or improving weight loss outcomes, with 75% of patients satisfied with the switch.